Japanese Chemicals Stock News

Sojitz group company Royal Healthcare in Singapore has begun offering NEC Corporation's FonesVisuas Test, an advanced blood test that estimates the risk of multiple diseases. This marks Sojitz's entry into predictive health testing in Southeast Asia through its partnership with NEC and Royal Healthcare. The move expands Sojitz's presence in healthcare, adding a new dimension to its business portfolio in the Asia Pacific region. For investors tracking Sojitz (TSE:2768), this development adds...

Iwatani (TSE:8088) is drawing fresh attention after announcing a CEO transition, with Akiji Makino moving to the role of Chairman and Hiroshi Majima becoming President and CEO on April 1, 2026. See our latest analysis for Iwatani. The CEO transition comes as Iwatani’s share price has shown firm momentum, with a 25.4% 90 day share price return and a 37.8% 1 year total shareholder return from a latest close of ¥2,066.5. If this leadership change has you thinking more broadly about opportunities...

Japan Real Estate Investment (TSE:8952) lifted its earnings and dividend guidance after agreeing to acquire additional office assets in Tokyo and Sapporo, alongside filing a follow on equity offering to fund this expanded portfolio. See our latest analysis for Japan Real Estate Investment. At a share price of ¥122,200, Japan Real Estate Investment has a 1-year total shareholder return of 14.65%. This is even though the 30-day share price return of 7.63% and the year-to-date share price return...

Elliott Investment Management’s new statement on Mitsui O.S.K. Lines (TSE:9104) has pushed investor attention toward the company’s upcoming medium term management plan and the question of how the market values its shipping assets. See our latest analysis for Mitsui O.S.K. Lines. The Elliott statement lands after a strong run in the share price, with a 30 day share price return of 23.39% and a 90 day share price return of 51.93%. The 5 year total shareholder return of roughly 7x signals that...

Guidance update and why it matters for Daiei Kankyo (TSE:9336) Daiei Kankyo (TSE:9336) drew investor attention after its March 24, 2026 board meeting, where the company approved new full year consolidated earnings forecasts for the fiscal year ending March 31, 2027. The guidance outlines expected net sales of ¥93,900 million, operating profit of ¥24,300 million and profit attributable to owners of parent of ¥15,000 million, with basic earnings per share projected at ¥150.23. See our latest...

NIKKON Holdings Ltd (TSE:9072) has wrapped up its share buyback program, repurchasing 4,227,100 shares, or 3.53% of its stock, for ¥14,999.86 million by March 24, 2026. See our latest analysis for NIKKON HoldingsLtd. The completion of the buyback comes during a strong run for the stock, with a 1 day share price return of 9.12% and a 90 day share price return of 54.18%. The 5 year total shareholder return is very large, indicating that momentum has been building rather than fading. If NIKKON's...

Why Tokyo Electron Is On Investors’ Radar Now Tokyo Electron (TSE:8035) has drawn attention after a sharp month pullback of about 13%, even as its past 3 months return sits around 14%. That gap is prompting closer scrutiny from investors. See our latest analysis for Tokyo Electron. The recent 13% one-month share price pullback to about ¥39,290 comes after a 14% three-month share price return and a very strong one-year total shareholder return of 84%. This suggests that short-term momentum has...

Mitsubishi Electric, Toshiba and Rohm are reported to be in talks to merge their power semiconductor device operations. The potential combination would create a larger Japanese player in power chips, an area supported by government policy and global demand trends. The development is seen as a material shift for Mitsubishi Electric’s power device business and its competitive position in TSE:6503. Mitsubishi Electric, listed as TSE:6503, is entering these merger talks with a share price of...

Wondering whether Nintendo's share price reflects its true value today, or if the market is missing something that you could be early to? The stock recently closed at ¥9,215, with a 5.5% gain over the last 30 days, although returns sit at a 13.5% decline year to date and a 14.7% decline over the last year, set against an 87.7% gain over 3 years and 63.7% over 5 years. Recent coverage has focused on how Nintendo fits into the broader entertainment and gaming sector, including discussion of...

Event context and recent share performance NSK (TSE:6471) has come into focus after recent share price moves, with the stock showing a 1.5% decline over the past day and a smaller slide over the past week. These short term shifts contrast with a larger fall over the past month and a sizeable gain across the past 3 months, prompting investors to reassess how current pricing lines up with NSK’s underlying business profile. See our latest analysis for NSK. Looking beyond the latest moves, NSK’s...

Investors in Kao Corporation ( TSE:4452 ) had a good week, as its shares rose 2.2% to close at JP¥6,147 following the...

Shareholders in Imperial Hotel, Ltd. ( TSE:9708 ) may be thrilled to learn that the covering analyst has just delivered...

Wondering whether HOYA's share price still makes sense after a strong run, or if expectations have run ahead of reality? This article walks through the key clues in the current valuation. Over the past year, HOYA has returned 56.4%, with the share price at ¥27,280 after a 13.1% gain year to date, even though the stock has seen a 6.6% pullback over the last month and a 1.9% decline in the past week. Recent coverage has focused on HOYA's position in healthcare equipment and related...

Toyota Motor (TSE:7203) is recalling more than 560,000 Highlander and Crown Kluger SUVs in China due to a second row seat safety defect. The recall affects vehicles sold by its joint venture with GAC and was recently announced to address potential safety risks. Separately, Toyota expanded its partnership with onX in the US through the Trail Revival Project, focused on restoring public land trails. The Trail Revival Project aims to improve access to outdoor recreation while supporting local...

If you are wondering whether OMRON at ¥4,469 is priced attractively, the answer depends on how you look at value and which metrics you trust most. The stock is up 11.8% year to date and 1.9% over the last year, even though it has seen a 2.1% slip over the past week and a 19.2% decline over the last month, and longer term returns over 3 and 5 years have been weaker at 39.1% and 46.8% declines. Recent price moves sit against a backdrop of ongoing interest in automation, robotics and industrial...

On March 18, 2026, Toho Co., Ltd.’s board approved sweeping leadership changes, including Representative Director Yoshishige Shimatani stepping down to become Corporate Adviser and the planned retirement of several senior Executive Officers across its real estate, theatrical, and cinema businesses. These shifts reshuffle decision‑making power across Toho’s core operating groups, potentially signaling an internal rethink of how its film, theater, and property operations are led. With these...

SoftBank Group (TSE:9984) has secured a $40b unsecured bridge loan underwritten by major global banks. The facility is intended to finance a planned $30b follow on investment in OpenAI. The move deepens SoftBank's alignment with OpenAI across AI hardware and software, including links to Arm Holdings. For you as an investor, this is a large capital commitment that puts SoftBank Group in a central position in the current AI cycle. The planned follow on stake in OpenAI connects directly with...

Rohto PharmaceuticalLtd (TSE:4527) has announced a share repurchase program, authorizing the buyback of up to 1,500,000 shares for ¥3,000 million. The initiative is intended to improve capital efficiency and support flexible capital policies. See our latest analysis for Rohto PharmaceuticalLtd. At a share price of ¥2,412.0, Rohto PharmaceuticalLtd has a 7 day share price return of 2.14% and a 1 year total shareholder return of 6.88%. The 3 year total shareholder return of 10.34% contrasts...

What recent performance says about DAIHEN (TSE:6622) With no single headline event driving attention today, DAIHEN (TSE:6622) is drawing interest because its share price has moved sharply in both directions over different periods, including a 17.4% decline over the past month. See our latest analysis for DAIHEN. That recent 17.4% 1 month share price decline sits against a 20.0% 3 month share price return and a very strong 86.65% 1 year total shareholder return. This suggests some momentum has...

Recent share performance context Kioxia Holdings (TSE:285A) has drawn attention after a sharp share price swing, with the stock showing a 4.2% decline over the past day and a 9.3% drop over the past week. See our latest analysis for Kioxia Holdings. Despite the recent pullback, with a 5.6% 1 month share price return decline, Kioxia Holdings still shows strong momentum when viewed over the year, highlighted by a 77.6% 3 month share price return and a very large 1 year total shareholder...

Event context and recent share performance Honda Motor (TSE:7267) has been drawing attention after recent share price swings, with the stock up around 1.5% over the past day but showing weaker performance over the past month and past 3 months. For investors, that mix of short term strength and recent declines raises questions about how current expectations around earnings, cash flows, and long term demand for Honda’s automobiles, motorcycles, and power products are being reflected in the...

Hokuriku Electric Power (TSE:9505) cut its profit outlook for the year ending March 31, 2026, after deciding to abolish the Fukui Thermal Power Station Mikuni Unit 1 and recognize related impairment losses. See our latest analysis for Hokuriku Electric Power. The board’s decision on Mikuni Unit 1 and the resulting downgrade to profit guidance comes against a backdrop of a 13.31% 90 day share price return and a 94.79% 3 year total shareholder return. This suggests recent momentum has built on...

Ono Pharmaceutical has submitted a manufacturing and marketing application in Japan for ripretinib, an oral tyrosine kinase inhibitor for advanced gastrointestinal stromal tumor that has progressed after prior chemotherapy, supported by positive global Phase 3 INVICTUS data showing significantly prolonged progression-free survival versus placebo. The filing is reinforced by ripretinib’s orphan drug status and its designation as a high medical-need therapy in Japan, highlighting its potential...

Investors may be wondering if ASICS at ¥4,306 is still offering value after its strong run, or if most of the easy gains are now behind it. The share price shows a mix of short term pressure and longer term strength, with a 2.2% decline over 7 days and a 7.8% decline over 30 days, set against an 11.9% gain year to date and a 35.9% return over the last year. Over a multi year horizon the stock has delivered very large returns, with the 3 year performance and the 5 year performance each...